Covid-19 News Elsevier and ExactCure review 20 drugs for Covid-19 therapies

Elsevier and ExactCure have announced a collaboration aimed at developing personalised model simulations to improve the dosing of Covid-19 related therapies. ExactCure is a personalised medicine

start-up that uses AI technology to reduce medication errors. Combining this platform with data from PharmaPendium, which includes searchable FDA/EMA drug approval documents as well as pharmacokinetic and efficacy data, will help to shed light on potential therapeutic targets. Fabien Astic, co-founder of ExactCure,

said: ‘We have been working with a university hospital in the south of France to provide the clinical pharmacologist and pharmacist the simulation-based suggestions. This allows them to quickly adapt their treatment decisions for a safer and more efficient use of these promising drugs, that while currently still under investigation, could potentially be critical and life-saving for many Covid-19 patients. Through this collaboration with Elsevier

to use PharmaPendium’s data we can accelerate this really important work.’ PharmaPendium will provide ExactCure with pharmacokinetic information for approximately 20 approved drugs that have been widely cited in the literature and the news, such as Hydroxychloroquine, Chloroquine, Lopinavir/Ritonavir and Azithromycin, including their regulatory- approval datasets. ExactCure will use this data to build drug-specific exposure models that allow the prediction of pharmacokinetic properties (e.g. Cmax, AUC, Tmax etc). The first step is to build a simulation

based on the patient’s age, weight, drug dosage, dosing time and end-time, resulting in a personalised therapeutic window

“The simulation will be enriched by adding more patient parameters”

ProQuest users gain free access to Covid-19 resources

ProQuest launched a Coronavirus Research Database, giving all ProQuest users no-cost access to full-text content covering all facets of Covid-19. The Coronavirus Research Database

saves time and improves outcomes for researchers by aggregating authoritative content from ProQuest with content made available at no cost by members of the International Association of STM Publishers – including Springer Nature, Taylor & Francis and The BMJ. Journals, preprints, conference proceedings and dissertations provide comprehensive coverage of COVID-19 and other past coronavirus outbreaks, such as MERS and SARS, for context around the current global pandemic. Full-text content in the database is available

researchers working on Covid-19, the new site is aimed at providing policymakers, governments, and lay people access to evidence-based answers to questions around Covid-19. There will also be an opportunity for interested members of the public to help by suggesting answers to problems that researchers and | @researchinfo

either directly from ProQuest or via links to publisher sites. ‘Opening up access to materials related

to COVID-19 will not only help clinicians, students and academics, but is also crucial for nurses – one of the many groups who are under siege right now, said Daphne Stannard, a lecturer at the San Francisco State University School of Nursing. ‘I’m pleased to see ProQuest make this content available to the people who need it.’ ‘Whether it’s the latest medical research

on how the virus is transmitted, preprints exploring new therapies to combat the virus, or editorials exploring lessons learned from prior outbreaks, faculty and students need quick and easy access to information to help them navigate this new world,’ said

practitioners are struggling with. Goel continued: ‘With the

overwhelming volume of research and information being produced on Covid-19, there needs to be a platform that allows researchers from various disciplines to easily access and digest this information, supported by expert opinion. And that’s exactly what we

Chris Burghardt, vice president of product management at ProQuest. ‘The Coronavirus Research Database was created as a tool to help our users to find the information they need to quickly explore the many facets of this disease.’ The database is automatically enabled at

no cost for all ProQuest platform customers, and can be accessed at search.proquest. com/coronavirus. Content will continue to evolve as new research and information emerges.

The launch of the Coronavirus Research

Database is the latest in a series of programs ProQuest is building to help libraries support the crucial research needed now to fight this disease as well as support distance learning for their patrons.

are offering – a platform that collates research and datasets from different countries, irrespective of the language in which they were published; allows researchers to ask questions and pose hypotheses to other researchers; and curates expert-driven editorial content that simplifies and explains the latest research.

‘We see this quickly

expanding to include on- demand webinars and podcasts, and evolving into a crowdfunding platform for research. Imagine the power of a platform where researchers across disciplines are coming together to learn from each other and find solutions to the pandemic collaboratively.’

June/July 2020 Research Information 11

between efficiency and over-exposure. This could potentially reduce the number of adverse drug events. Furthermore, the simulation will be enriched by adding more patient parameters, such as renal status, which is also a critical factor for many severe patients. ‘As the pandemic deepens, hundreds of clinical trials have been set up to test existing medications against Covid-19,’ said Olivier Barberan, director of translational medicine solutions at Elsevier. ‘Elsevier has taken its work further by sharing PharmaPendium data to support ExactCure in building the ‘digital twin’ that simulates in-silico the efficacy and interactions of drugs in the body of a patient based on their personal characteristics. This can be extremely helpful for the clinical pharmacologists and frontline doctors in the development of safe and effective treatment. We are looking forward to continuing this work with ExactCure to help reduce the impact of this global pandemic.’

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36